AT13148

Cancer Research UK · Phase 1 active Biologic

At a glance

Generic name	AT13148
Sponsor	Cancer Research UK
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I Study of AT13148, a Novel AGC Kinase Inhibitor (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AT13148 CI brief — competitive landscape report
AT13148 updates RSS · CI watch RSS
Cancer Research UK portfolio CI